Objectives: To evaluate the safety, tolerability and pharmacokinetics of ESBA105 administered topically to the eye for up to 28 days in healthy volunteers. To determine the systemic exposure to ESBA105 upon single and repeated-dose topical application to the eye in healthy volunteers.
ESBA105 is an anti TNF single chain antibody fragment
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
27
eye drops
Swiss Pharma Contract
Basel, Switzerland
safety and tolerability
Time frame: several timepoints
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.